Galapagos reported EUR70.17M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
argenx SE USD 842.5M 132.26M Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Biogen USD 2.6B 170M Jun/2025
Genmab DKK 5.86B 580M Jun/2025
Gilead Sciences USD 7.1B 430M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
GRIFOLS EUR 1.89B 100M Jun/2025
Hikma Pharmaceutical USD 1.59B 18M Dec/2024
Incyte USD 1.06B 10M Jun/2025
Merck EUR 4.43B 850M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Sanofi EUR 9.99B 90M Jun/2025
UCB EUR 3.49B 129M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025